Leukeran (chlorambucil)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Chlorambucil, a nitrogen mustard-derivative, bifunctional alkylating agent, is an antineoplastic agent.
Chlorambucil has been used in the treatment of various malignant and nonmalignant diseases; however, because of its carcinogenic potential, the drug should be used with extreme caution, if at all, in the treatment of nonmalignant diseases. (See Cautions: Mutagenicity and Carcinogenicity.)
Generic name: chlorambucil
Pronunciation: (klor-AM-bue-sil)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Leukeran
Indications
The following indications are listed for Leukeran:
- Chronic Lymphoid Leukemia
- Follicular Lymphoma
- Hodgkin's Lymphoma
Also known as: Anemia Lymphatica, Follicular B-Cell Lymphoma, Follicular B-Cell Non-Hodgkin's Lymphoma, Hodgkin's Disease.
Dosing
No dosing information is available for this tab.
Chlorambucil is administered orally.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Chlorambucil can cause fetal harm when administered to pregnant women, but potential benefits from use of the drug may be acceptable in certain conditions despite the possible risks to the fetus. It has been reported that in 2 women who received chlorambucil during early pregnancy and had therapeutic abortions, the fetuses had unilateral absence of a kidney and ureter; this anomaly has also been observed in the offspring of pregnant rats receiving the drug. Therefore, chlorambucil should be used during pregnancy only in conditions such as life-threatening situations or for disease for which safer drugs cannot be used or are ineffective. If the drug is administered during pregnancy or if the patient becomes pregnant while receiving the drug, the patient should be informed of the potential hazard to the fetus.
It is not known if chlorambucil is distributed into milk. Because of the potential for serious adverse reactions from chlorambucil in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.